These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10942927)

  • 21. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC; Canales MA; Ojeda E; de Bustos JG; Aguado MJ; Hernández-Navarro F
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
    Fan Y; Huang ZY; Luo LH; Yu HF
    Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
    Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
    Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
    Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
    Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
    Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
    Rigacci L; Carpaneto A; Alterini R; Carrai V; Bernardi F; Bellesi G; Longo G; Bosi A; Rossi Ferrini P
    Cancer; 2003 Jan; 97(1):97-104. PubMed ID: 12491510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
    Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
    Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly.
    Zinzani PL; Bendandi M; Gherlinzoni F; Mazza P; Salvucci M; Aitini E; Miggiano MC; Gozzetti A; Tura S
    Haematologica; 1993; 78(6):378-82. PubMed ID: 7513674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bendamustine, vincristine, prednisolone (BOP) in therapy of advanced low-grade non-Hodgkin lymphoma]].
    Kath R; Blumenstengel K; Fricke HJ; Peters HD; Höffken K
    Dtsch Med Wochenschr; 2001 Feb; 126(8):198-202. PubMed ID: 11256023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy of DACE regimen on relapsed and refractory non-Hodgkin's lymphoma].
    Zhang MZ; Zang WP; Song M; Geng L; Li X; Wang RL
    Ai Zheng; 2008 Apr; 27(4):435-7. PubMed ID: 18423133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
    Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
    Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
    Santini G; Contu A; Porcellini A; Chisesi T; Coser P; Congiu AM; Morandi S; Manna A; Schintu GM; Quaini R
    Haematologica; 1991; 76(6):485-90. PubMed ID: 1820985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
    Shaklai S; Bairey O; Blickstein D; Prokocimer M; Hadar H; Lahav M; Sulkes J; Shaklai M
    Cancer; 1996 Jun; 77(11):2313-7. PubMed ID: 8635101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.